Title |
“Snake-oil,” “quack medicine,” and “industrially cultured organisms:” biovalue and the commercialization of human microbiome research
|
---|---|
Published in |
BMC Medical Ethics, October 2012
|
DOI | 10.1186/1472-6939-13-28 |
Pubmed ID | |
Authors |
Melody J Slashinski, Sheryl A McCurdy, Laura S Achenbaum, Simon N Whitney, Amy L McGuire |
Abstract |
Continued advances in human microbiome research and technologies raise a number of ethical, legal, and social challenges. These challenges are associated not only with the conduct of the research, but also with broader implications, such as the production and distribution of commercial products promising maintenance or restoration of good physical health and disease prevention. In this article, we document several ethical, legal, and social challenges associated with the commercialization of human microbiome research, focusing particularly on how this research is mobilized within economic markets for new public health uses. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 6 | 25% |
France | 3 | 13% |
United Kingdom | 2 | 8% |
Unknown | 13 | 54% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 15 | 63% |
Scientists | 8 | 33% |
Practitioners (doctors, other healthcare professionals) | 1 | 4% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 3% |
Denmark | 1 | <1% |
Germany | 1 | <1% |
Switzerland | 1 | <1% |
Unknown | 107 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 19 | 17% |
Student > Ph. D. Student | 17 | 15% |
Student > Master | 17 | 15% |
Student > Bachelor | 10 | 9% |
Other | 9 | 8% |
Other | 20 | 18% |
Unknown | 21 | 19% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 33 | 29% |
Medicine and Dentistry | 13 | 12% |
Biochemistry, Genetics and Molecular Biology | 12 | 11% |
Nursing and Health Professions | 6 | 5% |
Social Sciences | 5 | 4% |
Other | 20 | 18% |
Unknown | 24 | 21% |